CML Publications of the Month
As part of our monthly news service we would like to make you aware of important CML publications. From the many papers published every month Professor Tim Hughes selects topical, interesting papers for your perusal. Papers with a clinical, scientific, pediatric and low and middle income country focus are shared.
February 2026
Clinical CML papers
Development of a prognostic scoring system for chronic myeloid leukemia in blast phase
Lauseker M et al. Leukemia, February 2026 (epub ahead of print)
open access publication
A plain language summary of how the body processes a lower-dose nilotinib tablet (DanzitenTM) compared with the existing capsule (Tasigna®)
Mauro M et al. Future Oncol, February 2026
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study
Iurlo A et al. Cancer, February 2026
open access publication
Extended long-term follow-up and the survival of Stop Imatinib Study
Mahon FX et al. Blood Neoplasia, February 2026
open access publication
Leveraging model-informed drug development to predict asciminib efficacy in second-line treatment of chronic myeloid leukemia in chronic phase
Sy SKB et al. Clin Pharmacokinet, February 2026 (epub ahead of print)
Pregnancy-related adverse events with tyrosine kinase inhibitor use in chronic myeloid leukemia: A FAERS Pharmacovigilance analysis (2001 – 2024)
Faisal MS et al. Clin Lymphoma Myeloma Leuk, February 2026
Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparable cohort study
Cheng F et al. BMC Cancer, February 2026 (epub ahead of print)
open access publication
Second- and third-generation BCR-ABL tyrosine kinase inhibitors and the risk of pulmonary arterial hypertension: A prevalent new-user design
Jambon-Barbara C et al. Circulation, February 2026 (epub ahead of print)
open access publication
A BCR::ABL1 exon 13 variant leads to systematic underestimation of transcript level in the molecular monitoring of CML
Boucher L et al. Leuk Res, February 2026 (epub ahead of print)
Evolving therapeutic algorithms in chronic myeloid leukemia: Integrating efficacy, safety, and survivorship
Leyfman Y et al. Biomedicines, February 2025
open access publication
The importance of bone marrow biopsy for chronic myeloid leukemia classification – a case report
Gonçalves NY et al. HJ Hematop, February 2026
open access publication
Should you be afraid of the big bad wolf? A practical real-world review for the comfortable use of bosutinib in the therapy of chronic myeloid leukemia
Lipton JH. J Cancer Immunol, December 2025
open access publication
Scientific CML papers
Intrinsic cellular resistance to BCR::ABL1 inhibitors
Cruz-Rodriguez N et al. Haematologica, February 2026 (epub ahead of print)
open access publication
ERK-mTOR crosstalk suppresses autophagy and upregulates proteasomal degradation pathway to confer chronic myeloid leukemia cells resistant to imatinib
Roy R et al. Exp Hematol, February 2026
High miR-202-5p expression at initial diagnosis is associated with tyrosine kinase inhibitor resistance in chronic myeloid leukemia – a result from a nested Case-Control Study
Nie ZY et al. EJHaem, February 2026
open access publication
Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients
Luukkainen K et al. Hemasphere, February 2026
open access publication
Peripheral blood neutrophil maturation as a predictor of treatment-free remission in CML
Fujita M et al. Int J Lab Hematol, February 2026 (epub ahead of print)
Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells
Atef B et al. Ann Hematol, February 2026
open access publication
Molecular background of Philadelphia chromosome dependent enhancement of cellular growth and tyrosine kinase inhibitor sensitivity
Hossain MF et al. Exp Hematol Oncol, February 2026
open access publication